Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 2, 2017, Pages 166-174

  Khanna, Sahil ^a   Shin, Andrea ^b   Kelly, Ciarán P ^c  

^a MAYO CLINIC   (United States)

^b INDIANA UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; IMMUNOSUPPRESSIVE AGENT; METRONIDAZOLE; STEROID; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DIAGNOSTIC TEST; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; EVIDENCE BASED MEDICINE; FECAL MICROBIOTA TRANSPLANTATION; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE COUNT; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL LITERATURE; PATIENT MONITORING; PATIENT REFERRAL; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; RECURRENT INFECTION; REVIEW; SCREENING TEST; SEPSIS; CLOSTRIDIUM INFECTIONS; COMPLICATION; ISOLATION AND PURIFICATION; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 85009354128     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.10.024     Document Type: Review

References (63)

1. 1 Leffler, D.A., Lamont, J.T., Clostridium difficile infection. N Engl J Med 373 (2015), 287–288.
2. 2 Cohen, S.H., Gerding, D.N., Johnson, S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31 (2010), 431–455.
3. 3 Bartlett, J.G., Chang, T.W., Gurwith, M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298 (1978), 531–534.
4. 4 Larson, H.E., Price, A.B., Honour, P., et al. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1 (1978), 1063–1066.
5. 5 Kelly, C.P., LaMont, J.T., Clostridium difficile–more difficult than ever. N Engl J Med 359 (2008), 1932–1940.
6. 6 Lessa, F.C., Mu, Y., Bamberg, W.M., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 825–834.
7. 7 McDonald, L.C., Owings, M., Jernigan, D.B., Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12 (2006), 409–415.
8. 8 McDonald, L.C., Killgore, G.E., Thompson, A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 (2005), 2433–2441.
9. 9 Loo, V.G., Poirier, L., Miller, M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005), 2442–2449.
10. 10 O'Connor, J.R., Johnson, S., Gerding, D.N., Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136 (2009), 1913–1924.
11. 11 LaMont, J.T., Trnka, Y.M., Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1 (1980), 381–383.
12. 12 Bossuyt, P., Verhaegen, J., Van Assche, G., et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis 3 (2009), 4–7.
13. 13 Rodemann, J.F., Dubberke, E.R., Reske, K.A., et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 5 (2007), 339–344.
14. 14 Ramos-Martinez, A., Ortiz-Balbuena, J., Curto-Garcia, I., et al. Risk factors for Clostridium difficile diarrhea in patients with inflammatory bowel disease. Rev Esp Enferm Dig 107 (2015), 4–8.
15. 15 Issa, M., Vijayapal, A., Graham, M.B., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 5 (2007), 345–351.
16. 16 Ananthakrishnan, A.N., McGinley, E.L., Binion, D.G., Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57 (2008), 205–210.
17. 17 Nguyen, G.C., Kaplan, G.G., Harris, M.L., et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 103 (2008), 1443–1450.
18. 18 Monaghan, T.M., Cockayne, A., Mahida, Y.R., Pathogenesis of Clostridium difficile infection and its potential role in inflammatory bowel disease. Inflamm Bowel Dis 21 (2015), 1957–1966.
19. 19 Dubberke, E.R., Olsen, M.A., Stwalley, D., et al. Identification of Medicare recipients at highest risk for Clostridium difficile infection in the US by population attributable risk analysis. PLoS One, 11, 2016, e0146822.
20. 20 Kyne, L., Warny, M., Qamar, A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 (2000), 390–397.
21. 21 Leffler, D.A., Lamont, J.T., Editorial: not so nosocomial anymore: the growing threat of community-acquired Clostridium difficile. Am J Gastroenterol 107 (2012), 96–98.
22. 22 Clayton, E.M., Rea, M.C., Shanahan, F., et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 104 (2009), 1162–1169.
23. 23 Kostic, A.D., Xavier, R.J., Gevers, D., The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146 (2014), 1489–1499.
24. 24 Frank, D.N., St Amand, A.L., Feldman, R.A., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104 (2007), 13780–13785.
25. 25 Machiels, K., Joossens, M., Sabino, J., et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63 (2014), 1275–1283.
26. 26 Giel, J.L., Sorg, J.A., Sonenshein, A.L., et al. Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One, 5, 2010, e8740.
27. 27 Allegretti, J.R., Kearney, S., Li, N., et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther 43 (2016), 1142–1153.
28. 28 Kyne, L., Warny, M., Qamar, A., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357 (2001), 189–193.
29. 29 Lowy, I., Molrine, D.C., Leav, B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362 (2010), 197–205.
30. 30 Jodorkovsky, D., Young, Y., Abreu, M.T., Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 55 (2010), 415–420.
31. 31 Khanna, S., Pardi, D.S., IBD: poor outcomes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol Hepatol 9 (2012), 307–308.
32. 32 Hu, M.Y., Katchar, K., Kyne, L., et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136 (2009), 1206–1214.
33. 33 Kelly, C.P., Can we identify patients at high risk of recurrent Clostridium difficile infection?. Clin Microbiol Infect 18:Suppl 6 (2012), 21–27.
34. 34 Garey, K.W., Sethi, S., Yadav, Y., et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 70 (2008), 298–304.
35. 35 Razik, R., Rumman, A., Bahreini, Z., et al. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol 111 (2016), 1141–1146.
36. 36 Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498 quiz 99.
37. 37 Debast, S.B., Bauer, M.P., Kuijper, E.J., et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20:Suppl 2 (2014), 1–26.
38. 38 Riggs, M.M., Sethi, A.K., Zabarsky, T.F., et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 45 (2007), 992–998.
39. 39 Furuya-Kanamori, L., Marquess, J., Yakob, L., et al. Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. BMC Infect Dis, 15, 2015, 516.
40. 40 Alasmari, F., Seiler, S.M., Hink, T., et al. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 59 (2014), 216–222.
41. 41 Planche, T.D., Davies, K.A., Coen, P.G., et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis 13 (2013), 936–945.
42. 42 Polage, C.R., Gyorke, C.E., Kennedy, M.A., et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 175 (2015), 1792–1801.
43. 43 Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498.
44. 44 Zar, F.A., Bakkanagari, S.R., Moorthi, K.M., et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007), 302–307.
45. 45 Pepin, J., Alary, M.E., Valiquette, L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40 (2005), 1591–1597.
46. 46 Musher, D.M., Aslam, S., Logan, N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40 (2005), 1586–1590.
47. 47 Johnson, S., Louie, T.J., Gerding, D.N., et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 59 (2014), 345–354.
48. 48 Louie, T.J., Miller, M.A., Mullane, K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364 (2011), 422–431.
49. 49 Mullane, K.M., Miller, M.A., Weiss, K., et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 53 (2011), 440–447.
50. 50 Bartsch, S.M., Umscheid, C.A., Fishman, N., et al. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 57 (2013), 555–561.
51. 51 Horton, H.A., Dezfoli, S., Berel, D., et al. Antibiotics for treatment of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease. Antimicrob Agents Chemother 58 (2014), 5054–5059.
52. 52 Spiceland, C., Khanna, S., Pardi, D.S., Outcomes of fidaxomicin treatment of Clostridium difficile infection. Gastroenterology, 150, 2015, S744.
53. 53 Jen, M.H., Saxena, S., Bottle, A., et al. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 33 (2011), 1322–1331.
54. 54 Kelly, C.R., Kahn, S., Kashyap, P., et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149 (2015), 223–237.
55. 55 Kelly, C.P., Current strategies for management of initial Clostridium difficile infection. J Hosp Med 7:Suppl 3 (2012), S5–S10.
56. 56 Kelly, C.R., Ihunnah, C., Fischer, M., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109 (2014), 1065–1671.
57. 57 Khoruts, A., Rank, K.M., Newman, K.M., et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 14 (2016), 1433–1438.
58. 58 Vermeire, S., Joossens, M., Verbeke, K., et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis 10 (2016), 387–394.
59. 59 Ben-Horin, S., Margalit, M., Bossuyt, P., et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol 7 (2009), 981–987.
60. 60 Ananthakrishnan, A.N., Guzman-Perez, R., Gainer, V., et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 35 (2012), 789–795.
61. 61 Yanai, H., Nguyen, G.C., Yun, L., et al. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators?. Inflamm Bowel Dis 17 (2011), 1540–1546.
62. 62 Issa, M., Ananthakrishnan, A.N., Binion, D.G., Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 14 (2008), 1432–1442.
63. 63 Epple, H.J., Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig Dis 27 (2009), 555–559.